The Chinese drug administration included Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) serplulimab injection in combination with chemotherapy for gastric cancer in the regulator's breakthrough therapy drug program, according to a Shanghai bourse filing on Friday.
A drug included in the program will accelerate its review and approval process for its designated indication.
The pharmaceutical company's subsidiary, Shanghai Henlius Biotech, developed the drug, which is also used as a treatment for lung cancer.
Fosun's Hong Kong shares slumped less than 4% and Shanghai shares fell over 1% during the morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments